Follows lung health and germs in children with cystic fibrosis
Observes lung function and germs in infants and children with cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Key facts
- Where
- Bern, SwitzerlandSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for infants and children up to 18 years old with cystic fibrosis found by newborn screening. It studies lung function, viral infections and the lung microbiota.
- Age
- 0 to 18 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed diagnosis of cystic fibrosis (CF) by newborn screening (NBS).
Main reasons for not taking part
- Needed breathing support for more than three days
- Severe malformations or known diseases other than CF
- Mother's drug abuse
- Known severe disease in the mother
- Pacemaker or continuous glucose monitor
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 18 years old?
Source: NCT04026360, who can take part
Where in Switzerland
- University Children's Hospital BernBern, SwitzerlandContact: Philipp Latzin, MD PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT04026360
- Record updated
- 4 November 2020
- Original description
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).Read full original descriptionShow less
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).
Inclusion: Infants with a confirmed diagnosis of CF by NBS; Age <=18 years; Written informed consent by patient and/or parent.
Exclusion: Maternal drug abuse; Severe malformations or known diseases other than CF; Known severe maternal disease; Pacemaker, continuous glucose monitor; Need for respiratory support for more than three days; Severe Problems of communication.